Member Info for TorquayFan

AB124. The first para of your 20.45 is a classic takedown of the posting of AI material here. Thankyou. Maybe AI was 'worth a try' but . . . . .

LL - I don't think your questions are treated as 'daft lassie' by anyone. Sorry to hear about your shoulder - maybe you should give up rugby.

Hello Violin, whilst I too agree with the sentence you quoted from Dracula, I disagree with your other comments.

To dismiss all future BMS interest in Scancell on the grounds of their deal with BioNTech is precipitate and of course we don't have any idea if for example, BioNTech are talking to Scancell about any of 'our' science.

And to propose that Merck is our ONLY hope is balderdash, (whilst Merck may of course be a strong contender). None of us know what talks are going on and with whom.

Finally I too enjoy Cleaner's posts regularly but I do think that to bring AI analysis onto the BB is a mistake - maybe that's a generational thing. ATB

Thanks C11. As you say, a 'cool' video. I noticed the talk was of iSCIB1+ alone, again.

Violin - I think you made your jolly comment when SP was 9 pence. IMO that was a bit below the belt old Chap! After all, at last, Scancell have lots to talk about with data to support it and who knows what discussions might have been rolling along to be continued. However, I confess, the next month or two will be a long wait for me too.

Nearly there, the science will see us through . . . .

Thanks Billy - don't think I've seen that before.

And Cleaner, though I'm not 'in', I could read that. But cheers.

WTP - yes ideal opportunity for networking on new . . . and/or continuing discussions.

Interesting to see the CMO in the front seat again with CEO. No sign again of our dear CSO and I'm sure she is happy going back to a science focus - who knows what she might turn up this time?

Marcus 20033 re. Stephen Diggle.

Stephen Diggle has relocated to Oxford from Singapore to follow BioTech, a Vulpes passion, (even though it has been a 'terrible market' since Covid). There's "never been a more advantageous time to invest in BioTech" and the "risk reward is unprecedentedly good". "World class IP has never been cheaper".

I think he likes it !

46 minutes https://www.youtube.com/watch?v=EWeFb5dKuGM&t=2768s&ab_channel=DavidLin

Thanks Marcus

Martin Diggle shows more personal faith and commitment in Scancell with he being a major player in Vulpes a major investor. Good to see. IMO an excellent move at this price with news due in the next month or two. Just wish I had £45K lying around so I could do the same!

Chester - for mid year, June 1 to July 31 seems right to me and indeed, CEO has expressed a renewed commitment to meeting timelines. We'll see . . . .

Jackdaw - thanks for your response. ATB

Looks interesting in 'Nature' https://www.nature.com/articles/s41568-025-00820-z

I can't get in. Anyone with access, please can you post the script?

Yes indeed, Rest In Peace C7. We remember visiting you 10 years ago at your home.

I'm guessing you'll be keeping an eye on our 'pivotal year', from up there.

Scanning YouTubes today, this brilliant piece with Dr Heather Shaw appeared again and I rewatched, closely from 29 minutes onwards. Scancell's science is clearly the subject when HS mentions exciting developments behind the scenes of the headline grabbing mRNA vaccines. HS talks about SCIB1 and iSCIB1+ at some length and with carefully expressed but obviously firm interest. This was posted before and discussed at length here but for any new watchers, here it is.

https://youtu.be/A-iNl8sShCM

Towards the end HS expresses interest in what effects adjusting the 'combo' might have, (i.e. less CI and more vaccine) and also, about the use of this vaccine at earlier stages.

It's quiet. For any new BB watchers . . . . .

Chester re. yours, agreed, let's hope administering Nivo by injection will improves outcomes - that would be good all round. I wonder if/when they will trial Nivo by Pharmajet?

RE. your 12.03 yesterday - it certainly caught the mood here - over 30 ticks now! I enjoyed it.

Hi Cleaner. Yes I saw that and reports in the DX etc. a few days ago. Of course, its not really a new treatment for cancers at all but an existing treatment that can now be deployed by injection, rather than IV drip. thus saving a great deal of time.

I suppose this is not helpful to Scancell except we have a vaccine to treat the condition that the Nivo is being used for e.g. melanoma.

I wondered if the NHS might later be able to administer Nivo by Pharmajet? That would be another step forward for them, (but wouldn't have much implication for 'us'). ATB

Conclusions:

SCIB1 in combination with nivolumab and ipilimumab as first line treatment for unresectable Stage 3/4 melanoma resulted in 80% 6-month PFS with strong vaccine specific T cell responses without an increase in clinically meaningful adverse events. These results, if confirmed, in a larger patient cohort provide confidence in initiating a randomized registration program in unresectable melanoma patients with our novel DNA plasmid technology.

Citation Format:Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Prasad Kellati, Ioannis Karydis, Maria Marples, Kate Young, Pippa Corrie, Robert Miller, Georgia Goodhew, Samantha Paston, Gaelle Cane, Joseph Chadwick, Sabaria Shah, Lindy G. Durrant, Nermeen Varawalla. A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB214. "

https://aacrjournals.org/cancerres/article/85/8_Supplement_2/LB214/761890/Abstract-LB214-A-DNA-plasmid-melanoma-cancer

Thanks Marcus

Marcus posted this yesterday 19941.

"Poster Presentations - Proffered Abstracts| April 25 2025

Abstract LB214: A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial

Background:

Targeting melanoma with T cells drives anti-tumor responses. We previously showed that a DNA vaccine, SCIB1, incorporating T cell epitopes from TRP-2/gp100 into an antibody framework to allow Fc targeting of activated dendritic cells, was successfully as a monotherapy in Stage 3/4 melanoma patients in a Phase 1/2 clinical study. Unresectable melanoma patients showed a 60% ORR and 88% of patients treated with SCIB1, post tumor resection, remained disease free for 5 years [1]. The current SCOPE trial tests the hypothesis that unresectable patients may have an improved response when SCIB1 is combined with checkpoint inhibitors (CPI) compared to CPI alone.

Methods:

Patients are treated with nivolumab with ipilimumab and SCIB1 (8mg) i.m. using needle-free injection at a fixed dosing schedule for up to 10 doses over 24 months. The CPI therapy is administered i.v. in accordance with their respective SmPC. ORR as measured by RECIST 1.1 in the overall intention-to-treat population is the primary endpoint. The study is designed using Simon's two stage methodology with 80% power when the true response rate is 70% versus 50% RR of no interest with an overall type I error of 5%. In the first stage, 15 patients needed to be enrolled and if there are eight or fewer clinical responses (RECIST 1.1 objective response [CR or PR] within 25 weeks of the first dose of SCIB1), further recruitment would have been stopped. The null hypothesis will be rejected if 27 or more responses are observed in 43 patients. T cell responses are assessed using a cultured ELISpot assay following TRP-2 or gp100 peptides stimulation

Results:

To date, 43 patients received the combination of SCIB1 with nivolumab and ipilimumab. 25 patients had reached 25 weeks, and had 80% PFS, 84% DCR and 72% ORR with 20% of patients showing a complete response. 94% (16/17) of the clinical responders had a T cell response, 80% (4/5) of the patients with stable disease had a T cell response, 33% (1/3) of patients with progressive disease had a T cell response. T cell receptors isolated from patients showed strong, peptide, ImmunoBody® and tumor recognition. Of interest was that in a patient who showed a pre-vaccinated response to the encoded epitope a different TCR was stimulated by the vaccine. Most of the SCIB1-related adverse events were Grade 1/2. The only Grade 3 related events were a rash, pulmonary embolism, neutropenia and raised GGT. No exacerbation of immune-mediated adverse events was observed when SCIB1 was added to nivolumab with ipilimumab . . . . . .

Chester re. the 'missed timelines', no doubt you saw Mr L'Huillier's recent commitment to meet timelines in future but the proof of the pudding is, we know where. GLA

Not crying but waiting and hoping with Buddy Holly for the SP to return even to the measly highs of recent years https://youtu.be/LWdJ7Dy-3iY

It's perhaps 8/12 weeks until we get to the 'near term milestones' of our 'data rich' 2nd half and that's gonna seem like a long time to this Scancellite! Did I miss an update from the recent AACR meeting? But news could come anytime now?

Mid 2025 - full data SCIB1 cohort 1

- full data iSCIB1+ cohort 3

Q3 2025 - Modi1 interim readouts renal cell carcinoma with CI

Q4 2025 - Modi1 head and neck ORR data

End 2025 - initial data iSCIB1+ intradermal with accelerated dosing, (courtesy of the NHS/CVLP).

From the horses mouth https://www.youtube.com/watch?v=8ARuWSMNNTM&ab_channel=InvestorMeetCompany

Come on Scancell - as Buddy says, "you're the one I love and I think about you all the time" (yuk).

Burble thanks for your posts and for waking up a sleepy BB a little on this long weekend!

There's no doubt Scancell are 'up and around' these days. Tick tock.

WTP many thanks for that link. Speaking for myself, I hadn't seen it before and it's, good stuff! Cheers.